Engineering of chimeric peptides as antagonists for the G protein-coupled receptor, RXFP4

Praveen Praveen; Ross AD Bathgate; Mohammed Akhter Hossain

Journal article

Engineering of chimeric peptides as antagonists for the G protein-coupled receptor, RXFP4

Praveen Praveen, Ross AD Bathgate, Mohammed Akhter Hossain

Scientific Reports | NATURE PUBLISHING GROUP | Published : 2019

DOI: 10.1038/s41598-019-53707-z

Download PDF

University of Melbourne Researchers

Akhter Hossain Author Florey Department of Neuroscience and Mental Health

Ross Bathgate Author Florey Department of Neuroscience and Mental Health

Related Projects (3)

INTERROGATING PEPTIDE RECEPTOR TARGETS

The neuropeptide relaxin-3 and the peptide hormone INSL5 are recently discovered members of the relaxin peptide family. Relaxin-3 has import..

Novel insulin to treat diabetes

The glucose regulatory hormone, insulin, remains the only treatment for type I diabetes and up to 30% of type II diabetes, both of which are..

Enhancing the clinical potential of relaxin

The hormone relaxin mediates cardiovascular and kidney changes during pregnancy. These important functions have led to its current use in cl..

Grants

Awarded by NHMRC (Australia)

Awarded by A.R.C. linkage grant

Funding Acknowledgements

This research was partly funded by NHMRC (Australia) project grants (1023321, 1065481, and 1023078) to M.A.H., R.A. D.B. and A.R.C. linkage grant (LP120100654) to M.A.H. and R.A.D. B. We are grateful to Tania Ferraro and Sharon Layfield for assistance with biochemical assays. RADB is an NHMRC Senior Research Fellow. Studies at the Florey Institute were supported by the Victorian Government's Operational Infrastructure Support Program.